MCID: PRP021
MIFTS: 46

Peripheral Nervous System Neoplasm malady

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Neoplasm

Aliases & Descriptions for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 12 14
Peripheral Nervous System Neoplasms 42 69
Nerve Sheath Tumors 12 69
Neoplasm of Peripheral Nerve 12
Nerve Sheath Neoplasms 42
Nerve Sheath Neoplasm 12
Tumor of Pns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1192
NCIt 47 C3321 C4972

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology : 12 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary : Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to malignant cardiac peripheral nerve sheath neoplasm and malignant triton tumor, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Apoptosis Modulation and Signaling and Development HGF signaling pathway. The drugs Acetaminophen and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include the peripheral nervous system, and related phenotypes are Decreased viability and behavior/neurological

Related Diseases for Peripheral Nervous System Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 malignant cardiac peripheral nerve sheath neoplasm 12.0
2 malignant triton tumor 11.0
3 autonomic nervous system neoplasm 10.9
4 acrodermatitis chronica atrophicans 10.4 ALK TP53
5 lung occult small cell carcinoma 10.4 NGF NTRK1 TP53
6 blood group incompatibility 10.4 ENO2 NGF TP53
7 gallbladder pleomorphic giant cell adenocarcinoma 10.4 ENO2 NGF TP53
8 cervical adenoid cystic carcinoma 10.4 NF1 TP53
9 adult epithelioid sarcoma 10.4 ENO2 NGF TP53
10 peripheral osteosarcoma 10.4 ENO2 MYC MYCN
11 childhood central nervous system primitive neuroectodermal neoplasm 10.4 ENO2 MYCN TP53
12 granulomatous myositis 10.4 ENO2 NF1 TP53
13 auriculocondylar syndrome 1 10.3 NGF NTRK1 NTRK2
14 jejunal somatostatinoma 10.3 CD34 ENO2 NF1
15 duodenal ulcer 10.3 MYC MYCN TP53
16 walker-warburg syndrome 10.3 NGF NTRK1 NTRK2
17 central nervous system hemangioma 10.3 ENO2 NF1 TP53
18 flat ductal epithelial atypia 10.3 ENO2 NF1 TP53
19 rh isoimmunization 10.3 ENO2 MYCN NTRK1 NTRK2
20 pleomorphic adenoma 10.3 CD34 MYC
21 myoepithelial carcinoma 10.3 ENO2 MYCN NTRK1 NTRK2
22 ossifying fibromyxoid tumor 10.3 CD34 ENO2 TP53
23 basophil adenoma 10.3 CD34 MYC
24 vascular myelopathy 10.3 CD34 NF1 TP53
25 childhood brain germinoma 10.3 ENO2 MYC MYCN TP53
26 gall bladder carcinoma in situ 10.3 MYC MYCN NGF NTRK1
27 urinary tract obstruction 10.3 ALK ENO2 MYCN NTRK2
28 childhood medulloblastoma 10.3 ENO2 MYC MYCN TP53
29 extragonadal germ cell cancer 10.3 MYC MYCN TP53
30 mongolian spot 10.3 ALK CD34 NF1
31 breast squamous cell carcinoma 10.3 CD34 ENO2 TP53
32 pharynx cancer 10.3 CD34 ENO2 NF1 TP53
33 nodular goiter 10.3 AKT1 ENO2 MYCN TP53
34 endocrine organ benign neoplasm 10.3 CD34 ENO2 NF1 TP53
35 connective tissue benign neoplasm 10.3 AKT1 CASP3 TP53
36 mediastinum sarcoma 10.3 CD34 ENO2 TP53
37 arteriosclerosis obliterans 10.3 CD34 TP53
38 rhabdomyosarcoma 2, alveolar 10.3 ENO2 MYCN TH
39 adult medulloblastoma 10.3 AKT1 CASP3 MYC TP53
40 ovarian lymphoma 10.3 CD34 MYC
41 trachea squamous cell carcinoma 10.3 AKT1 CASP3 MYC TP53
42 gestational choriocarcinoma 10.3 AKT1 CD34 ENO2 TP53
43 ovarian mucinous adenocarcinoma 10.3 AKT1 CASP3 NGF TH
44 bardet-biedl syndrome 10.3 AKT1 CASP3 MYC TP53
45 alpha chain disease 10.3 AKT1 ENO2 TP53
46 melanoma metastasis 10.3 AKT1 CASP3 MYC TP53
47 sarcocystosis 10.3 ALK CD34
48 chondrodysplasia punctata, rhizomelic, type 3 10.2 CASP3 TP53
49 substance-induced psychosis 10.2 CASP3 MFRP NGF TH
50 gastrointestinal stromal tumor 10.2 AKT1 CD34 ENO2 NF1 TP53

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

GenomeRNAi Phenotypes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.47 ALK MYC NF1 NTRK2 AKT1
2 Decreased viability GR00221-A-2 9.47 NF1 NTRK2 AKT1
3 Decreased viability GR00221-A-3 9.47 MYC AKT1
4 Decreased viability GR00221-A-4 9.47 ALK NF1 NTRK2 AKT1

MGI Mouse Phenotypes related to Peripheral Nervous System Neoplasm:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 TP53 AKT1 ALK CASP3 CNTN6 ENO2
2 growth/size/body region MP:0005378 10.42 AKT1 ALK CASP3 ENO2 MYC MYCN
3 cellular MP:0005384 10.35 AKT1 CASP3 CD34 ENO2 MYC MYCN
4 nervous system MP:0003631 10.33 ENO2 MFRP MYC MYCN NF1 NFIC
5 mortality/aging MP:0010768 10.32 AKT1 ALK CASP3 MYC MYCN NF1
6 homeostasis/metabolism MP:0005376 10.3 AKT1 ALK CASP3 CD34 MYC MYCN
7 integument MP:0010771 10.21 CASP3 CD34 MYC NF1 NGF NTRK1
8 normal MP:0002873 10.11 AKT1 MYC MYCN NF1 NGF NTRK1
9 craniofacial MP:0005382 10.1 CASP3 ENO2 MYC MYCN NF1 NFIC
10 hearing/vestibular/ear MP:0005377 10.08 CASP3 MYC NF1 NTRK1 NTRK2 NUMBL
11 muscle MP:0005369 10.06 AKT1 CASP3 MYC MYCN NF1 NGF
12 liver/biliary system MP:0005370 10.04 TH TP53 AKT1 MYC MYCN NF1
13 neoplasm MP:0002006 9.98 AKT1 ALK CD34 MYC NF1 TH
14 reproductive system MP:0005389 9.91 AKT1 ALK CASP3 MYC MYCN NFIC
15 pigmentation MP:0001186 9.87 ALK CASP3 MFRP MYC NF1 NTRK1
16 respiratory system MP:0005388 9.85 ALK CASP3 ENO2 MYCN NF1 NTRK2
17 skeleton MP:0005390 9.61 NTRK2 TP53 AKT1 ALK CASP3 MYC
18 vision/eye MP:0005391 9.36 ALK CASP3 MFRP MYCN NF1 NGF

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1323)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
2
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474
3
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 437-38-7 3345
5
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 74103-06-3, 66635-83-4 3826
6
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 57-27-2 5288826
7
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2078-54-8 4943
8
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
9
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
11
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
12
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
13
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
14
Levobupivacaine Approved Phase 4,Phase 2,Phase 3 27262-47-1 92253
15
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59467-70-8 4192
16
Remifentanil Approved Phase 4,Phase 3,Phase 1,Phase 2 132875-61-7 60815
17
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 169590-42-5 2662
18 Parecoxib Approved Phase 4,Phase 3 198470-84-7
19
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
20
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
21
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 170729-80-3 151165 6918365
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
23
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1 172673-20-0 219090
24
Palonosetron Approved, Investigational Phase 4,Phase 3,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
25
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
26
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
27
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
28
Rocuronium Approved Phase 4,Phase 2,Phase 3,Phase 1 119302-91-9, 143558-00-3 441290
29
Basiliximab Approved, Investigational Phase 4,Phase 2 152923-56-3, 179045-86-4
30
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
31
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 159351-69-6 6442177
32
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
33
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
34
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
35
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
37
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53123-88-9 5284616 6436030 46835353
38
Adalimumab Approved Phase 4,Phase 2 331731-18-1 16219006
39
Certolizumab pegol Approved Phase 4 428863-50-7
40
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 185243-69-0
41
Infliximab Approved Phase 4,Phase 2 170277-31-3
42
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
43
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
44
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
45
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2 161796-78-7, 119141-88-7 4594 9579578
46
Famotidine Approved Phase 4,Phase 2 76824-35-6 3325
47
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
48
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
49
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
50
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890

Interventional clinical trials:

(show top 50) (show all 4671)
id Name Status NCT ID Phase
1 Paracetamol for Cancer Pain Unknown status NCT01313247 Phase 4
2 Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia Unknown status NCT02103946 Phase 4
3 Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Unknown status NCT01459666 Phase 4
4 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4
5 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4
6 A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain Unknown status NCT02289261 Phase 4
7 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4
8 Quadratus Lumborum Block for Percutaneous Nephrostomy Unknown status NCT02121951 Phase 4
9 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4
10 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
11 Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy Unknown status NCT00129597 Phase 4
12 Palonosetron Associated to Aprepitant in Prophylaxis of PONV Unknown status NCT02431286 Phase 4
13 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4
14 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4
15 Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation Unknown status NCT00903188 Phase 4
16 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4
17 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4
18 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4
19 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4
20 A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair Unknown status NCT01470157 Phase 4
21 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4
22 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4
23 Prevention of Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block Unknown status NCT02144766 Phase 4
24 Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? Unknown status NCT01609855 Phase 4
25 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
26 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4
27 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
28 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
29 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4
30 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4
31 Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4
32 Impact of Various Sedation Regimens on the Incidence of Delirium Unknown status NCT02117726 Phase 4
33 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Unknown status NCT01712295 Phase 4
34 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4
35 Pathophysiology of Post Amputation Pain Completed NCT01632709 Phase 4
36 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4
37 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4
38 Symptom Management After Breast Cancer Surgery Completed NCT00686127 Phase 4
39 An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain Completed NCT00766831 Phase 4
40 An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer Completed NCT01006356 Phase 4
41 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4
42 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4
43 Chlorhydrate of Ropivacaine and Breast Cancer Surgery Completed NCT00370240 Phase 4
44 Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively Completed NCT02566096 Phase 4
45 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
46 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4
47 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4
48 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4
49 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4
50 PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain Completed NCT01719757 Phase 4

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Peripheral Nervous System Neoplasm:

18
The Peripheral Nervous System

Publications for Peripheral Nervous System Neoplasm

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

Pathways related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 AKT1 CASP3 MYC NGF NTRK1 TP53
2
Show member pathways
12.74 AKT1 CASP3 NGF NTRK1 NTRK2 TP53
3 12.61 AKT1 CASP3 MYC NTRK1 TP53
4
Show member pathways
12.38 AKT1 CASP3 NTRK1 NTRK2 TP53
5 12.38 ENO2 MYCN NF1 NGF NTRK1 NTRK2
6
Show member pathways
12.29 AKT1 CASP3 MYC TP53
7 12.24 AKT1 CASP3 MYC TP53
8 12.19 AKT1 CASP3 MYC NF1 NGF NTRK1
9 12.17 MYC MYCN NTRK1 TP53
10 12.12 AKT1 CASP3 MYC TP53
11 12.1 CASP3 NGF NTRK2 PHOX2B TH
12 12.06 AKT1 CASP3 MYC NF1 TP53
13 12.01 AKT1 CASP3 NGF NTRK1 NTRK2
14
Show member pathways
11.92 AKT1 CASP3 MYC NGF NTRK1 TP53
15 11.89 AKT1 MYC NF1 TP53
16 11.74 AKT1 MYC TP53
17 11.67 AKT1 CASP3 TP53
18
Show member pathways
11.64 AKT1 CASP3 NGF TP53
19 11.62 AKT1 MYC NTRK1 TP53
20
Show member pathways
11.58 NGF NTRK1 NTRK2
21 11.51 AKT1 CASP3 TP53
22 11.41 AKT1 CASP3 MYC TP53
23
Show member pathways
11.38 AKT1 CASP3 MFRP MYC NTRK1 NTRK2
24 11.37 AKT1 CNTN6 MYC MYCN TP53
25 11.33 AKT1 CASP3 MYC TP53
26 11.26 AKT1 CASP3 NGF
27 11.17 MYC NTRK1 TP53
28 10.79 CASP3 NTRK2
29
Show member pathways
10.65 NGF NTRK1 NTRK2
30 10.29 MYC MYCN

GO Terms for Peripheral Nervous System Neoplasm

Cellular components related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.02 AKT1 ALK MYC NTRK1 TP53

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 AKT1 ALK CD34 MYC TP53
2 nervous system development GO:0007399 9.93 AKT1 ALK CNTN6 NTRK1 NTRK2 NUMBL
3 positive regulation of apoptotic process GO:0043065 9.91 AKT1 CASP3 NF1 NGF TP53
4 negative regulation of gene expression GO:0010629 9.87 AKT1 CD34 MYC MYCN
5 protein autophosphorylation GO:0046777 9.86 AKT1 ALK NTRK1 NTRK2
6 cellular response to organic cyclic compound GO:0071407 9.79 AKT1 CASP3 MYC
7 cerebral cortex development GO:0021987 9.78 NF1 NTRK2 TH
8 neuron differentiation GO:0030182 9.78 CASP3 CNTN6 NTRK2 PHOX2B
9 cellular response to drug GO:0035690 9.77 MYC TH TP53
10 cellular response to growth factor stimulus GO:0071363 9.76 AKT1 NTRK1 TH
11 negative regulation of neuron death GO:1901215 9.72 AKT1 CD34 NTRK1
12 positive regulation of neuron apoptotic process GO:0043525 9.71 CASP3 NF1 TP53
13 response to nicotine GO:0035094 9.67 CASP3 NTRK1 TH
14 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 ALK NGF NTRK1 NTRK2
15 negative regulation of astrocyte differentiation GO:0048712 9.62 MYCN NF1
16 response to gamma radiation GO:0010332 9.61 MYC TP53 TRIM13
17 cellular response to nicotine GO:0071316 9.59 NTRK1 TH
18 phosphatidylinositol-mediated signaling GO:0048015 9.56 AKT1 NGF NTRK1 TP53
19 mechanoreceptor differentiation GO:0042490 9.52 NTRK1 NTRK2
20 negative regulation of fibroblast proliferation GO:0048147 9.5 MYC NF1 TP53
21 positive regulation of gene expression GO:0010628 9.43 CD34 MYC MYCN NGF NTRK2 TP53
22 neurotrophin signaling pathway GO:0038179 9.4 NTRK1 NTRK2
23 sympathetic nervous system development GO:0048485 9.33 NF1 NTRK1 PHOX2B
24 neurotrophin TRK receptor signaling pathway GO:0048011 8.8 CASP3 NGF NTRK1
25 negative regulation of apoptotic process GO:0043066 10.02 AKT1 CASP3 MYC NGF TP53

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 ALK NTRK1 NTRK2
2 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK2
3 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK2

Sources for Peripheral Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....